PDT Partners’s Teva Pharmaceuticals TEVA Stock Holding History

PDT Partners’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-67,409	Closed	-$3.98M	–	1556
2015 Q2	$3.98M	Buy	+67,409	New	+$4.16M	0.1%	241
2014 Q3	–	Sell	-205,239	Closed	-$10.8M	–	1585
2014 Q2	$10.8M	Sell	205,239 -59,982	-23%	-$3.07M	0.29%	72
2014 Q1	$14M	Buy	+265,221	New	+$12.3M	0.34%	70

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

PDT Partners's TEVA Position: Q3 2015 in Review

PDT Partners sold out of Teva Pharmaceuticals (TEVA) in Q3 2015, closing a stake of 67,409 shares — an estimated $3.98M sold.

PDT Partners first reported a position in TEVA in Q1 2014 and held it in 3 quarters. The position peaked at $14M in Q1 2014. 823 funds tracked by Wall St. Rank hold TEVA as of Q3 2015.

PDT Partners reported no remaining Teva Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
PDT Partners sold 67,409 Teva Pharmaceuticals shares in Q3 2015, an estimated $3.98M.
PDT Partners first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 3 quarters.
PDT Partners's Teva Pharmaceuticals position peaked at $14M in Q1 2014.
823 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2015.

Based on PDT Partners's 13F filing for Q3 2015, filed 16 Nov 2015.